Adoptive T cell therapy of solid tumors: time to team up with immunogenic chemo/radiotherapy.
Reads0
Chats0
TLDR
In this article, the authors highlight the beneficial effects of combining ACT with conventional chemo and/or radiotherapy, while originally classified as immunosuppressive, these methodologies can also promote the engraftment of ACT products, immunogenic cell death, and the reprogramming of more favorable microenvironments.About:
This article is published in Current Opinion in Immunology.The article was published on 2022-02-01 and is currently open access. It has received 13 citations till now. The article focuses on the topics: Immunogenic cell death & Radiation therapy.read more
Citations
More filters
Journal ArticleDOI
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
TL;DR: This review focuses on the progress and challenges of CAR-T cell therapy in hematological malignancies, such as attractive therapeutic targets,CAR-T related toxicities, and resistance to CAR- T cell therapy, and provides some practical recommendations.
Journal ArticleDOI
Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours
TL;DR: The current literature studies and understanding of the parameters that affect the chimeric antigen receptor T cells (CAR-T's) activation, effector function, in vivo persistence, and antitumour effects are reviewed.
Journal ArticleDOI
A review on contemporary nanomaterial-based therapeutics for the treatment of diabetic foot ulcers (DFUs) with special reference to the Indian scenario
TL;DR: The present nanomaterial-based techniques provide a strong base for future therapeutic approaches for skin regeneration strategies in the treatment of diabetic wounds and emerging therapeutics such as bioengineered skin substitutes and nanomMaterial-based innovative approaches such as antibacterial hyperthermia therapy and gene therapy for the Treatment of DFUs are highlighted.
Journal ArticleDOI
CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
TL;DR: In this paper , the authors discuss the limitations of CAR-T cell therapy in multiple myeloma (MM) patients, and summarize some optimization strategies to overcome these challenges, including optimizing CAR structure, such as utilizing dual-targeted/multi-targeted CAR-Ts and armored CART cells, optimizing manufacturing processes, combing CAR-t cell therapy with existing or emerging therapeutic approaches, and performing subsequent anti-myeloma therapy as salvage therapy or maintenance/consolidation therapy.
Journal ArticleDOI
Glycoconjugate Nanoparticle-Based Systems in Cancer Immunotherapy: Novel Designs and Recent Updates
TL;DR: Based on the progress in therapeutic design, predictions can be made as to what the future holds for increasing the percentage of positive patient outcomes for optimized systems.
References
More filters
Journal ArticleDOI
Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells.
Lenka V. Hurton,Lenka V. Hurton,Harjeet Singh,Amer Najjar,Kirsten Switzer,Tiejuan Mi,Sourindra Maiti,Simon Olivares,Brian Rabinovich,Helen Huls,Marie Andrée Forget,Vrushali Datar,Partow Kebriaei,Dean A. Lee,Richard E. Champlin,Laurence J.N. Cooper,Laurence J.N. Cooper +16 more
TL;DR: Results demonstrate that CAR+ T cells can develop long-term persistence with a memory stem-cell phenotype sustained by signaling through mbIL15, and may contribute to improving the safety and therapeutic efficacy of CAR-based immunotherapies of patients with advanced cancer.
Journal ArticleDOI
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
Biliang Hu,Jiangtao Ren,Yanping Luo,Brian Keith,Regina M. Young,John Scholler,Yangbing Zhao,Carl H. June +7 more
TL;DR: In an intact mouse tumor model, CD19-IL-18 CAR T cells induced deeper B cell aplasia, significantly enhanced CAR T cell proliferation, and effectively augmented antitumor effects in mice with B16F10 melanoma point to a strategy to develop universalCAR T cells for patients with solid tumors.
Journal ArticleDOI
Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Stephanie L. Goff,Mark E. Dudley,Deborah Citrin,Robert Somerville,John R. Wunderlich,David N. Danforth,Daniel Zlott,James Chih-Hsin Yang,Richard M. Sherry,Udai S. Kammula,Christopher A. Klebanoff,Michael S. Hughes,Nicholas P. Restifo,Michelle M. Langhan,Thomas E. Shelton,Lily Lu,Mei Li M. Kwong,Sadia Ilyas,Nicholas D. Klemen,Eden C. Payabyab,Kathleen E. Morton,Mary Ann Toomey,Seth M. Steinberg,Donald E. White,Steven A. Rosenberg +24 more
TL;DR: Adoptive cell transfer can mediate durable complete regressions in 24% of patients with metastatic melanoma, with median survival > 3 years.
Journal ArticleDOI
CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors
Markus Chmielewski,Hinrich Abken +1 more
TL;DR: Systematic screening indicates that IL-18 polarizes CAR T cells toward T-bethigh FoxO1low effectors with an acute inflammatory response, suggesting that "iIL18 TRUCKs" can be used to sensitize large solid tumor lesions for successful immune destruction.
Journal ArticleDOI
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Fiona C Thistlethwaite,Fiona C Thistlethwaite,David E. Gilham,Ryan D. Guest,Dominic G. Rothwell,Manon Pillai,Manon Pillai,Deborah J. Burt,Andrea J. Byatte,Natalia Kirillova,Juan W. Valle,Juan W. Valle,Surinder K. Sharma,Kerry A. Chester,Nigel B. Westwood,Sarah E. R. Halford,Stephen Nabarro,Susan Wan,Eric Austin,Robert E. Hawkins,Robert E. Hawkins +20 more
TL;DR: Improved CAR designs and T cell production methods could improve the systemic persistence and activity, methods to control CAR T ‘on-target, off-tissue’ toxicity are required to enable a clinical impact of this approach in solid malignancies.